Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005875 · ClinicalTrials.gov registry record · NA
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
A NA study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01005875 is a NA study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 5 participants.
The verdict
NCT01005875, a NA study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
Interventions
- DRUG Sorafenib
- RADIATION Stereotactic Body Radiotherapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005875
The ClinicalTrials.gov registry entry for NCT01005875 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01005875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005875 about?
NCT01005875 is a clinical study titled "Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma". This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
What is the current status of trial NCT01005875?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2009-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01005875?
The interventions under investigation include: Sorafenib (DRUG), Stereotactic Body Radiotherapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01005875?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.